AstraZeneca and IMS Health Announce Data and Research Collaboration
On Jan. 11, 2012, AstraZeneca and IMS Health announced a three-year collaboration to use real-world healthcare data from Europe to guide AstraZeneca?s discovery and clinical development programs.
On Jan. 11, 2012, AstraZeneca and IMS Health announced a three-year collaboration to use real-world healthcare data from Europe to guide AstraZeneca’s discovery and clinical development programs. The partnership will give AstraZeneca access to de-identified electronic health records, which include clinical outcomes, economic, and treatment pattern data. In addition, the companies will jointly develop a customized research and data-analysis platform.
The information will be used to analyze how medicines that are already on the market are being used in real-world clinical applications, and to elucidate the standard of care and treatment patterns across several therapeutic areas, with an emphasis on chronic illnesses. AstraZeneca aims to use the analysis to allocate its R&D and clinical development resources more effectively. Martin Mackay, AstraZeneca’s president of R&D, said in a press release: “Our collaboration with IMS is a key milestone in our commitment to understand the impact of our medicines in the real world, beyond what we see in controlled clinical trials. This insight will help us and healthcare decision-makers to improve the treatment of disease and ensure effective use of medicines to minimize the burden on individuals and healthcare budgets.”
The collaboration with IMS Health to use European health information to analyze real-world healthcare trends follows a similar agreement between AstraZeneca and HealthCore, the health outcomes research subsidiary of WellPoint. The partnership with HealthCore was announced in February 2011, and aims to analyze US healthcare data to find ways of improving overall patient health while lowering the total cost of care—especially in the treatment of chronic diseases.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
AES Clean Technology Launches Next-Generation OSM Utility Solution for Cleanrooms at INTERPHEX 2025
April 2nd 2025Officially launched at INTERPHEX 2025, the Omni ASCENT is a next-generation off-site manufactured vertical utility solution that offers optimized cleanroom flexibility and efficiency.
